Literature DB >> 20572

Comparative effects of antacids, cimetidine and enteric coating on the therapeutic response to oral enzymes in severe pancreatic insufficiency.

P T Regan, J R Malagelada, E P DiMagno, S L Glanzman, V L Go.   

Abstract

To provide a rational basis for pancreatic enzyme replacement therapy, we evaluated, in six patients with advanced pancreatic insufficiency, the effects of various treatment regimens on fecal fat and nitrogen balance and on duodenal recovery of ingested pancreatic enzymes after a solid test meal. The combination of cimetidine (an H2-receptor antagonist) and pancreatin, each given by mouth, produced significantly higher postprandial duodenal recoveries and concentrations of trypsin and lipase (P less than 0.05). Steatorrhea was reduced in all patients and abolished in four of the six. In the dosages used, neither enteric-coated enzymes nor supplemental neutralizing antacids were more effective than pancreatin alone in decreasing steatorrhea or improving duodenal enzyme delivery. Cimetidine may be a useful adjunct to oral pancreatic extract therapy in some patients with severe pancreatic insufficiency who fail to respond to pancreatic enzyme replacement alone.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 20572     DOI: 10.1056/NEJM197710202971603

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  51 in total

Review 1.  Pancreatic enzyme replacement therapy.

Authors:  P Layer; J Keller; P G Lankisch
Journal:  Curr Gastroenterol Rep       Date:  2001-04

2.  Transverse sternotomy for concomitant cardiac and pulmonary surgery.

Authors:  E E Eren; D A Ott
Journal:  Tex Heart Inst J       Date:  1984-06

3.  Monitoring enzyme replacement treatment in exocrine pancreatic insufficiency using the cholesteryl octanoate breath test.

Authors:  S Mundlos; P Kühnelt; G Adler
Journal:  Gut       Date:  1990-11       Impact factor: 23.059

Review 4.  Human pancreatic exocrine response to nutrients in health and disease.

Authors:  J Keller; P Layer
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

5.  Optimising the therapy of exocrine pancreatic insufficiency by the association of a proton pump inhibitor to enteric coated pancreatic extracts.

Authors:  J E Domínguez-Muñoz; J Iglesias-García; M Iglesias-Rey; M Vilariño-Insua
Journal:  Gut       Date:  2006-07       Impact factor: 23.059

Review 6.  Improving the stability and activity of oral therapeutic enzymes-recent advances and perspectives.

Authors:  Gregor Fuhrmann; Jean-Christophe Leroux
Journal:  Pharm Res       Date:  2013-11-02       Impact factor: 4.200

7.  A perspective on the use of tubeless pancreatic function tests in diagnosis.

Authors:  E P DiMagno
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

Review 8.  Pancreatic enzymes in chronic pancreatitis.

Authors:  P Layer; G Holtmann
Journal:  Int J Pancreatol       Date:  1994-02

9.  A review of the Zollinger-Ellison syndrome--with particular reference to a patient treated with cimetidine.

Authors:  R J Wyke; G L Hill; A T Axon
Journal:  Postgrad Med J       Date:  1979-10       Impact factor: 2.401

10.  Delayed release pancrelipase for treatment of pancreatic exocrine insufficiency associated with chronic pancreatitis.

Authors:  Devi Mukkai Krishnamurty; Atoosa Rabiee; Sanjay B Jagannath; Dana K Andersen
Journal:  Ther Clin Risk Manag       Date:  2009-07-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.